Cell Therapy Drug Product Development: Technical Considerations and Challenges

被引:4
|
作者
Weng, Lindong [1 ]
机构
[1] Novo Nordisk Res Ctr Seattle Inc, Seattle, WA 98109 USA
关键词
Cryopreservation; Controlled-rate freezer; Cryoprotectant; Formulation; Fill and finish; Stability; Dose preparation; CAR T; CRYOPRESERVATION;
D O I
10.1016/j.xphs.2023.08.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cell therapy uses living cells as a drug to treat diseases. To develop a cell therapy drug product (DP), cryopreservation plays a central role in extending the shelf life of these living medicines by pausing their biological activities, especially preventing degradation, at a temperature as low as liquid nitrogen. This helps overcome the temporal and geographical gaps between centralized manufacturing and clinical administration, as well as allowing sufficient time for full release testing and flexibility in scheduling patients for administration. Cryopreservation determines or influences several key manufacturing, logistical, or clinical in-use processes, including formulation, filling, controlled rate freezing, cryogenic storage and transportation, thawing, and dose preparation. This article overviews the key technical aspects of cell therapy DP development and elucidates fundamental principles of cryobiology that should be considered when we design and optimize the relevant processes. This article also discusses the challenges that motivate continued innovation for cell therapy drug product development.(c) 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2615 / 2620
页数:6
相关论文
共 50 条
  • [21] Pluripotent stem cells for drug development and therapy: bioprocess development challenges
    Alves, Paula M.
    ANNALS OF MEDICINE, 2019, 51 : S22 - S22
  • [22] Opportunities and Challenges in Cell and Gene Therapy Development
    Brophy G.
    Genetic Engineering and Biotechnology News, 2019, 39 (11): : 21 - 22
  • [23] Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development
    Li, Min
    Sander, Sanna
    Duan, John
    Rosencrance, Susan
    Miksinski, Sarah Pope
    Yu, Lawrence
    Seo, Paul
    Rege, Bhagwant
    AAPS JOURNAL, 2016, 18 (06): : 1406 - 1417
  • [24] Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development
    Min Li
    Sanna Sander
    John Duan
    Susan Rosencrance
    Sarah Pope Miksinski
    Lawrence Yu
    Paul Seo
    Bhagwant Rege
    The AAPS Journal, 2016, 18 : 1406 - 1417
  • [25] TOTAL BRAIN THERAPY - TECHNICAL CONSIDERATIONS
    GREEN, N
    GEORGE, F
    RADIOLOGY, 1970, 96 (02) : 429 - &
  • [26] Technical inheritance in product development
    Gottwald, Philipp
    Sauthoff, Bastian
    Lachmayer, Roland
    Konstruktion, 2015, 67 (7-8):
  • [27] SAFETY CONSIDERATIONS IN PRODUCT DEVELOPMENT
    HAYES, AH
    DRUG SAFETY, 1990, 5 : 24 - 26
  • [28] Collaborative product development considerations
    Ottosson, S
    HUMAN BEHAVIOUR IN DESIGN: INDIVIDUALS, TEAMS, TOOLS, 2003, : 164 - 173
  • [29] Concise Review: Process Development Considerations for Cell Therapy
    Campbell, Andrew
    Brieva, Thomas
    Raviv, Lior
    Rowley, Jon
    Niss, Knut
    Brandwein, Harvey
    Oh, Steve
    Karnieli, Ohad
    STEM CELLS TRANSLATIONAL MEDICINE, 2015, 4 (10) : 1155 - 1163
  • [30] Regulatory challenges and considerations for the clinical application of CAR T cell therapy
    Bachmeier, Christina A.
    Kurian, Tony J.
    Davila, Marco L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (05) : 549 - 552